RESULTS WITH DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN A PHASE II COHORT OF PATIENTS WITH HER2-MUTANT OR AMPLIFIED LUNG CANCERS

被引：0
|
作者：
Kris, Mark G. [1 ]
Camidge, David Ross [2 ]
Giaccone, Giuseppe [3 ]
Hida, Toyoaki [4 ]
O'Connell, Joseph
Taylor, Ian
Zhang, Hui
Gold-Berg, Zelanna
Jaenne, Pasi A. [5 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Colorado, Boulder, CO 80309 USA
[3] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA
[4] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
[5] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
dacomitinib; tyrosine kinase inhibitor; Lung cancer; phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-032
引用
收藏
页码：S609 / S610
页数：2
相关论文
共 50 条
  • [1] DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR (TKI), FOR FIRST-LINE TREATMENT OF EGFR-MUTANT OR HER2-MUTANT OR -AMPLIFIED LUNG CANCERS
    Kris, M.
    Goldberg, Z.
    Janne, P. A.
    Kim, D.
    Martins, R.
    Mok, T. S. K.
    O'Connell, J.
    Ou, S.
    Taylor, I.
    Zhang, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 401 - 402
  • [2] FIRST-LINE DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, FOR PATIENTS WITH EGFR-MUTANT LUNG CANCERS
    Kris, M. G.
    Mok, T.
    Ou, S. -H. I.
    Martins, R. G.
    Kim, D. -W.
    Goldberg, Z.
    Zhang, H.
    Taylor, I.
    Letrent, S. P.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2012, 23 : 34 - 34
  • [3] First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers
    Kris, Mark G.
    Mok, Tony
    Ou, Sai-Hong Ignatius
    Martins, Renato
    Kim, Dong-Wan
    Goldberg, Zelanna
    Zhang, Hui
    Taylor, Ian
    Letrent, Stephen P.
    Janne, Pasi Antero
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
    Kalous, Ondrej
    Conklin, Dylan
    Desai, Amrita J.
    O'Brien, Neil A.
    Ginther, Charles
    Anderson, Lee
    Cohen, David J.
    Britten, Carolyn D.
    Taylor, Ian
    Christensen, James G.
    Slamon, Dennis J.
    Finn, Richard S.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (09) : 1978 - 1987
  • [5] Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors
    Kris, M. G.
    Camidge, D. R.
    Giaccone, G.
    Hida, T.
    Li, B. T.
    O'Connell, J.
    Taylor, I.
    Zhang, H.
    Arcila, M. E.
    Goldberg, Z.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1421 - 1427
  • [6] Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC
    Janne, P. A.
    Schellens, J. H.
    Engelman, J. A.
    Eckhardt, S. G.
    Millham, R.
    Denis, L. J.
    Britten, C. D.
    Wong, S. G.
    Boss, D. S.
    Camidge, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF FIRST-LINE DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN PATIENTS WITH LUNG CANCERS HARBORING EGFR EXON 21 MUTATION OR EGFR EXON 19 DELETION
    Mok, Tony
    Kris, Mark G.
    Ou, Sai-hong I.
    Martins, Renato G.
    Kim, Dong-wan
    Goldberg, Zelanna
    Zhang, Hui
    Taylor, Ian
    O'Connell, Joseph
    Doherty, Jim
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S453 - S453
  • [8] Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
    Zhu, Liancheng
    Lopez, Salvatore
    Bellone, Stefania
    Black, Jonathan
    Cocco, Emiliano
    Zigras, Tiffany
    Predolini, Federica
    Bonazzoli, Elena
    Bussi, Beatrice
    Stuhmer, Zachary
    Schwab, Carlton L.
    English, Diana P.
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Rutherford, Thomas J.
    Santin, Alessandro D.
    TUMOR BIOLOGY, 2015, 36 (07) : 5505 - 5513
  • [9] A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib
    Reckamp, Karen L.
    Giaccone, Giuseppe
    Camidge, D. Ross
    Gadgeel, Shirish M.
    Khuri, Fadlo R.
    Engelman, Jeff A.
    Koczywas, Marianna
    Rajan, Arun
    Campbell, Alicyn K.
    Gernhardt, Diana
    Ruiz-Garcia, Ana
    Letrent, Stephen
    Liang, Jane
    Taylor, Ian
    O'Connell, Joseph P.
    Jaenne, Pasi A.
    CANCER, 2014, 120 (08) : 1145 - 1154
  • [10] Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
    Le Tourneau, C.
    Winquist, E.
    Hotte, S. J.
    Laurie, S. A.
    Soulieres, D.
    Chia, S. K.
    Singh, S.
    Wang, T.
    Mormont, C.
    Siu, L. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345